Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... The global market for human vaccines ... of new vaccines. These new products and other ... The Kalorama information report examines the global market ... vaccines for diseases that are already vaccine-preventable. ... communities from diseases spread by person-to-person transmission. The ...
(Date:10/27/2014)... Calif. , Oct. 27, 2014  RenovoRx, a ... blood flow and delivery of fluids to selected sites ... Board of Directors has appointed Shaun Bagai ... of the RenovoRx Board of Directors. Bagai brings more ... industry. Bagai joined RenovoRx in June 2014 ...
(Date:10/27/2014)... 27, 2014  In the last few weeks, Ebola has gone ... to a worldwide crisis when a traveler to ... died, and two nurses were infected. While much of ... use of modern technology, such as electronic health records (EHRs), to ... This week, InformationWeek Healthcare Editor Alison Diana fills in ...
Breaking Medicine Technology:Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3RenovoRx Board Names Shaun R. Bagai as CEO 2EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3
... 2012 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... leading domestic developer, manufacturer and marketer of orthopedic ... operating subsidiaries, Beijing Libeier Biology Engineering Research Institute ... Ltd, have received approvals from relevant PRC authorities ...
... MAPLE GROVE, Minn., Jan. 11, 2012  Snow tires? Check! ... Just like a car, you need to prepare your ... extreme temperature changes can result in skin that is ... brakes on severe dry skin before it starts with ...
Cached Medicine Technology:China Kanghui Holdings Renews High and New Technology Enterprises Status of Its PRC Operating Subsidiaries 2Don't Let Your Skin Take a Backseat As You Prepare for Winter 2Don't Let Your Skin Take a Backseat As You Prepare for Winter 3
(Date:10/30/2014)... Home Care Assistance – Halton/Peel Region ( ... senior care, is weighing in on a recent study ... study, performed by the University of Illinois, analyzed 88 ... a week-long period and observed how much time was ... examining the structural soundness of the white matter in ...
(Date:10/30/2014)... FL (PRWEB) October 30, 2014 ... Joint Commission Accredited teleradiology and specialty telemedicine solutions ... in addition to its existing teleradiology services at ... second opinion and expert telemedicine services, to the ... , As a result of this innovative partnership, ...
(Date:10/30/2014)... 2014 Victory Healthcare, a privately ... third quarter infection rates and patient satisfaction scores. ... of only two percent or less, and the ... 98 percent. , “We are delighted with our ... satisfaction scores,” said Robert Helms, chairman and CEO ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. ... chemical during pregnancy may have effects on genital development in ... baby boys born to moms with greater exposure to a ... -- the space between the genitals and anus. Anogenital distance ... of exposure to androgens ("male" hormones) during pregnancy. The ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Americans, opinions ... political lines, a new study finds. Democratic voters ... (ACA), according to the researchers. Almost three-quarters of Democrats ... ACA. Thirty percent want Congress to implement the current ... of the ACA. Among Independent voters, one-third want ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... in the retina that is responsible for maintaining the health ... in a living retina for the first time. , The ... identify the onset of many diseases of the eye long ... issue of Investigative Ophthalmology and Visual Science ., "Our ...
... Tired of Putting Money in the Hands of Beauty Corporations ... / or Counseling to Remain Youthful? Now one does ... Never Before Published Secrets to Eternal Youth and Immortality, gives ... so that folks can attain and maintain the Age they ...
... Jade Goody who will be left behind without a ... Chantel "Chani" Christie who recently won the 2009 Martin ... is set to donate proceeds from her debut album ... star, Jade Goody. In addition, she also plans to ...
... facility already ahead of scheduleMARLTON, N.J., Feb. 25 ... exempt bonds from the New Jersey Health Care Facilities ... The bonds will be used to continue the financing ... our plan for finance in place and have met ...
... continued positive cash flow from operationsBOSTON, Feb. 25 ... a leader in radiology and medical image and ... for the fourth quarter and year ended December ... Financial Highlights Revenue : Total revenue for ...
... Feb. 25 Mesa Laboratories, Inc. (Nasdaq: ... manufacturing quality control applications, today announced the appointment of ... extensive experience to Mesa from his role as Chief ... Inc., a registered investment adviser based in New York ...
Cached Medicine News:Health News:'Dark cells' of living retina imaged for the first time 2Health News:'Dark cells' of living retina imaged for the first time 3Health News:What the Billion Dollar Beauty Industry Does Not Want Leaked: That One Can Actually Reverse Aging for Free by Moving Only to the Right. We Smell a Nobel. 2Health News:Chantel 'Chani' Christie Will Donate Proceeds From Her Top-Selling Debut Album 'My Dream' to the Children of Terminally Ill TV Star Jade Goody 2Health News:Virtua Health Takes Next Step for Continuing Hospital Construction 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 3Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 4Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 5Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 6Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 7Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 8Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 9Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 10Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 11Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 12Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 13Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 14Health News:Mesa Labs Announces Appointment of New Director 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve....
Goldman single hook....
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl...
Medicine Products: